BackgroundVaricose veins and the complications of venous disease are common disorders
in humans.ObjectiveTo study the effects of bleomycin as a potential new sclerosing agent and its
adverse events in treating varicose veins.MethodsBleomycin-loaded liposomes 0.1ml was injected in the dorsal ear veins of
white New Zealand rabbits. Sodium tetradecyl sulfate was used as a positive
control. Normal saline was used as negative control. The blood vessels of
the treated ears were photographed before and at one hour and two, eight and
45 days after treatment. Biopsies from the treated areas were obtained for
histological examination. Blood samples were collected to determine any
possible toxicity.ResultsBleomycin by itself was ineffective; therefore, liposomes were used as a
vector to deliver bleomycin to the vein lumen. Subsequently, bleomycin
started showing its sclerosing effects. Toxicity monitoring showed no
apparent hematologic, pulmonary, hepatic or renal toxicities. This study
revealed that bleomycin induced vasculitis, which led to vascular occlusion,
which was observed on day 1 and day 8. No bleomycin-related injury was noted
by histopathological examination of lung sections. The calculation of the
lung/body weight coefficient indicated that edema was present in the
experimental groups compared with the negative and positive controls.Study limitationsRelatively small number of experimental animals used.ConclusionsThis study showed that bleomycin-loaded liposomes were able to induce
vasculitis and vascular occlusion without any toxicity or complications. It
might be useful, hence, to treat patients suffering from Varicose veins and
other ectatic vascular diseases with this agent.